Neuropathies with antibodies against disialylated gangliosides and MAG

TargetsGangliosides GD1b, GQ1b, GT1aGangliosides GD1b, GD3, GT1b, GQ1bMAG + SGPG or SGLPG
Isotype IgG IgM IgM 
Kappa = lambda Kappa > lambda 
Mono/polyclonal Polyclonal Monoclonal Monoclonal 
Evolution Acute, reversible Chronic Chronic 
Syndrome Miller Fisher CANDA Anti-MAG neuropathy 
 Clinical signs  Ophthalmoplegia, ataxia, areflexia  Sensory ataxia, paresthesia, hypoesthesia, areflexia  Distal demyelinating symmetric sensory and motor neuropathy, ataxia, tremor 
Acute ataxic neuropathy CANOMAD 
 Idem, no ophthalmoplegia  + ophthalmoplegia and cold agglutinin 
Underlying clonal hematologic disease No MGUS IgM 66% MGUS IgM 80% 
Waldenström disease Waldenström disease 
Low-grade B-cell lymphoma Low-grade B-cell lymphoma 
Treatment IVIG IVIG, rituximab-based regimens Rituximab-based regimens 
TargetsGangliosides GD1b, GQ1b, GT1aGangliosides GD1b, GD3, GT1b, GQ1bMAG + SGPG or SGLPG
Isotype IgG IgM IgM 
Kappa = lambda Kappa > lambda 
Mono/polyclonal Polyclonal Monoclonal Monoclonal 
Evolution Acute, reversible Chronic Chronic 
Syndrome Miller Fisher CANDA Anti-MAG neuropathy 
 Clinical signs  Ophthalmoplegia, ataxia, areflexia  Sensory ataxia, paresthesia, hypoesthesia, areflexia  Distal demyelinating symmetric sensory and motor neuropathy, ataxia, tremor 
Acute ataxic neuropathy CANOMAD 
 Idem, no ophthalmoplegia  + ophthalmoplegia and cold agglutinin 
Underlying clonal hematologic disease No MGUS IgM 66% MGUS IgM 80% 
Waldenström disease Waldenström disease 
Low-grade B-cell lymphoma Low-grade B-cell lymphoma 
Treatment IVIG IVIG, rituximab-based regimens Rituximab-based regimens 

or Create an Account

Close Modal
Close Modal